Sonoma Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on January 14, 2022. The report discloses the completion of the company's annual stock option grant program to employees, executive officers, and directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on compensatory arrangements and does not contain financial performance data.
Material Changes
The primary event reported is the grant of stock options with an exercise price of $4.57 per share, based on the closing stock price on January 14, 2022. The grants vest in three equal tranches at six, 18, and 30 months from the grant date, with accelerated vesting upon a change of control.
Guidance, Outlook, and Management Commentary
Management stated the annual grant is intended to recognize employees meeting specific criteria and to retain key personnel. The filing does not provide forward-looking guidance, risk factors, or contingencies beyond the standard terms of the option grants.
Key Facts for Investor Verification
- Grant Date: January 14, 2022.
- Exercise Price: $4.57 per share.
- Recipients and Allocation:
- Each Director: 30,000 options.
- Amy Trombly (CEO): 30,000 options.
- Jerry Dvonch (CFO): 30,000 options.
- Bruce Thornton (COO): 30,000 options.
- Vesting Schedule: Three equal tranches at 6, 18, and 30 months.
- Termination Clause: Unvested options expire if employment terminates prior to the vesting date.